ConvaTec
Trial Pipeline
EDX110 Randomized Control Trial for Treatment of DFUs
NCT07209358
IDEAL: Efficacy of Porcine Placental Extracellular Matrix Augmented Plus Standard of Care (SOC) Versus SOC Alone for the Management of Diabetic Foot Ulcers
NCT06616844
INNOVEN: Efficacy of Porcine Placental Extracellular Matrix Plus Standard of Care (SOC) Versus SOC Alone
NCT06606210
Observational Study to Investigate the Use of Sterilized Porcine Placental Tissue in the Treatment of Chronic VLU
NCT06400875
Sterilised, Porcine Placental Tissue in the Treatment of Chronic Diabetic Foot Ulcers
NCT05687656
GentleCath™ for Men Intermittent Catheter With FeelClean™ Technology
NCT05470751
One Piece Closed Pouch in Subjects With a Colostomy
NCT01935999
One Piece Drainable Pouch in Subjects With an Ileostomy
NCT01939106
Comparison Study of 3 Ostomy Products
NCT01691729
Assess the Safety and Adhesive Performance of the VIPER System When Compared to Esteem™
NCT01261988
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 2 |
Therapeutic Areas
What the Pipeline for ConvaTec Shows
According to the ClinicalTrials.gov registry, ConvaTec is linked to 10 US clinical trials across every stage of research activity. Of those, 3 studies are currently recruiting — about 30% of the sponsor's indexed portfolio — and 5 are already marked complete, representing roughly 50% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for ConvaTec reports 0 late-stage studies (Phase 3 and Phase 4 combined) and 3 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for ConvaTec is Wound Heal with 4 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.